Monitoring
Monitoring is recommended every 6 months to 12 months for potential malignant transformation of existing AKs into squamous cell carcinoma (SCC) in situ (Bowen disease) or invasive SCC.[78]
More frequent monitoring is warranted in high-risk patients, such as immunosuppressed, organ-transplanted patients, xeroderma pigmentosum patients, patients with albinism, and patients with strong risk factors (e.g., outdoor workers, sports players, light-colored skin, middle-aged or older men).[12]
Use of this content is subject to our disclaimer